What is 3billion?
3billion operates at the intersection of advanced genomics and clinical diagnostics. Based in South Korea, the company specializes in gene sequencing and the development of sophisticated screening technology designed to identify rare diseases with high precision. By leveraging large-scale data analysis and proprietary AI-driven diagnostic tools, 3billion addresses the significant diagnostic gap often faced by patients with rare genetic disorders. The company's market position is defined by its commitment to transforming complex genomic data into actionable clinical insights, thereby providing essential support to healthcare providers and patients alike. Through its focus on high-growth biotech sectors, 3billion continues to attract significant institutional backing, reflecting its role as a key player in the evolution of precision medicine.
How much funding has 3billion raised?
3billion has raised a total of $291M across 3 funding rounds:
Series A
$268M
Series B
$10M
Series C
$13M
Series A (2018): $268M with participation from JW Assets, The Wells Investment, and Korea Development Bank
Series B (2019): $10M led by The Wells Investment, JW Assets, and Korea Development Bank
Series C (2021): $13M supported by Kakao Investment, Aventures Investment, The Wells Investment, Yuanta Investment, Magna Investment, JW Assets, and KOREA INVESTMENT & SECURITIES
Key Investors in 3billion
The Wells Investment
A South Korean venture capital and private equity firm focused on fostering sustainable growth in bio-healthcare, deep tech, and IT services through strategic capital and management expertise.
JW Assets
A consulting and investment firm providing strategic business management, risk analysis, and capital support to corporations and growth-stage enterprises.
Korea Development Bank
A state-owned policy development bank in South Korea dedicated to financing major industrial projects and fostering the competitiveness of strategic national industries.
What's next for 3billion?
Following the successful closure of its latest funding round, 3billion is poised to enter a phase of aggressive operational scaling and international market expansion. The strategic deployment of these funds will likely prioritize the enhancement of its diagnostic platform, the expansion of its clinical research partnerships, and the optimization of its global distribution channels. As the company transitions from its current growth stage toward broader commercialization, the focus will remain on maintaining its competitive edge in the rare disease screening market. Investors and industry observers will be monitoring the firm's ability to translate its technological advancements into sustained clinical adoption and long-term value creation within the rapidly evolving biotech ecosystem.
See full 3billion company page
